Orchid Pharma Share Price | Orchid Pharma Stock Screener
ORCHPHARMA
Pharmaceuticals
Share Price NSE
₹761.35
▲
37.00 (5.11%)
Share Price BSE
₹761.65
▲
39.70 (5.50%)
As of May 27, 2026, the Orchid Pharma share price (NSE: ORCHPHARMA) is ₹761.35 on NSE and ₹761.65 on BSE, up 5.11% from the previous close, with shares trading between ₹705.15 and ₹768.65, and a 52-week range of ₹482.45–₹871.95.
Check ORCHPHARMA yearly price range for the annual price range and momentum.
Use the Orchid Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Orchid Pharma Market Cap
₹3,583.30 Cr.
ORCHPHARMA P/E Ratio (TTM)
190.11
Orchid Pharma P/B Ratio
2.82
EPS (TTM)
₹19.65
Dividend Yield
-
Debt to Equity
0.13
ORCHPHARMA 52 Week High
₹871.95
Orchid Pharma 52 Week Low
₹482.45
Operating Margin
12.00%
Profit Margin
9.13%
ORCHPHARMA Revenue (TTM)
₹241.00
EBITDA
₹32.00
Net Income
₹22.00
Total Assets
₹1,688.00
Total Equity
₹1,267.00
Orchid Pharma Share Price Chart
Screen Orchid Pharma share price with an interactive chart. Analyse ORCHPHARMA price trends and volatility across different timeframes.
Orchid Pharma Company Profile - Fundamental Screener
Screen Orchid Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ORCHPHARMA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE191A01027
Orchid Pharma Balance Sheet Screener
Screen ORCHPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,688 | 1,554 | 1,225 | 1,111 | 1,237 | 1,460 | 3,077 | 3,125 | 3,256 | 3,862 |
| Current Assets | 807 | 791 | 501 | 398 | 550 | 569 | 768 | 679 | 675 | 1,251 |
| Fixed Assets | 633 | 620 | 573 | 584 | 670 | 858 | 1,256 | 1,386 | 1,497 | 1,637 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 135 | 124 | 165 | 222 | 442 | 519 | 1,436 | 1,905 | 2,212 | 2,475 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,267 | 1,170 | 689 | 647 | 653 | 766 | -704 | -792 | -467 | 49 |
| Share Capital | 51 | 51 | 41 | 41 | 41 | 41 | 89 | 89 | 89 | 89 |
| Reserves & Surplus | 1,148 | 1,050 | 579 | 538 | 544 | 725 | -793 | -881 | -556 | -40 |
Orchid Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Orchid Pharma income statement and profit fundamentals.
Analyze ORCHPHARMA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Orchid Pharma share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 241 | 184 | 204 | 213 | 231 | 252 | 230 | 226 | 251 | 185 | 207 | 228 | 180 | 134 | 171 |
| Expenses | 210 | 159 | 195 | 213 | 188 | 212 | 192 | 191 | 177 | 161 | 175 | 185 | 154 | 119 | 147 |
| EBITDA | 32 | 26 | 9 | 0 | 42 | 40 | 38 | 35 | 74 | 24 | 32 | 43 | 26 | 15 | 24 |
| Operating Profit % | 12.00% | 8.00% | -1.00% | -3.00% | 13.00% | 13.00% | 14.00% | 12.00% | 16.00% | 12.00% | 12.00% | 16.00% | 13.00% | 10.00% | 11.00% |
| Depreciation | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 9 | 7 | 8 | 8 | 9 | 27 | 22 | 18 |
| Interest | 4 | 3 | 4 | 3 | 4 | 4 | 3 | 4 | 8 | 6 | 4 | 4 | 5 | 8 | 9 |
| Profit Before Tax | 19 | 14 | -3 | -12 | 30 | 28 | 26 | 23 | 59 | 11 | 20 | 30 | -6 | -14 | -3 |
| Tax | -3 | -1 | 2 | 1 | -3 | -1 | -1 | 2 | 0 | 1 | 0 | 1 | 1 | 1 | 2 |
| Net Profit | 22 | 15 | -6 | -13 | 33 | 29 | 27 | 21 | 59 | 9 | 20 | 29 | -7 | -15 | -5 |
| EPS | 4.40 | 2.94 | -1.13 | -2.49 | 6.81 | 5.79 | 5.37 | 4.10 | 14.49 | 1.85 | 4.30 | 6.18 | -1.61 | -3.68 | -1.32 |
Orchid Pharma Cash Flow Screener - Liquidity Fundamentals
Screen ORCHPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 19 | 126 | 18 | 93 | 24 | 81 | 12 | 9 | 401 | 212 |
| Investing Activities | -27 | -312 | -31 | 113 | 67 | 167 | 46 | -28 | -176 | -2 |
| Financing Activities | 25 | 167 | 31 | -217 | -165 | -250 | 0 | 33 | -465 | -286 |
| Net Cash Flow | 18 | -19 | 18 | -11 | -74 | -2 | 57 | 15 | -240 | -76 |
Orchid Pharma Shareholding Pattern Screener
See Orchid Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Orchid Pharma promoter holding and ownership changes for ORCHPHARMA on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% |
| FII Holding | 0.87% | 2.69% | 1.40% | 1.56% | 1.17% | 1.96% | 1.42% | 1.94% |
| DII Holding | 20.25% | 20.10% | 19.43% | 19.04% | 19.39% | 17.73% | 18.93% | 18.29% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.58% | 5.11% | 6.91% | 7.03% | 6.76% | 7.44% | 7.16% | 7.59% |
| Other Holding | 2.47% | 2.27% | 2.43% | 2.54% | 2.84% | 3.03% | 2.65% | 2.35% |
| Shareholder Count | 35,118 | 34,303 | 39,827 | 38,155 | 35,709 | 36,720 | 34,695 | 36,363 |
Orchid Pharma Share Dividend Screener - Share Yield Analysis
Check Orchid Pharma dividend history with payout and yield data.
View Orchid Pharma dividend details including ex-dates and amounts for ORCHPHARMA stock.
Orchid Pharma Stock Index Membership
See which indices include Orchid Pharma stock.
Check ORCHPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Orchid Pharma Market Events Screener - Corporate Actions
Get Orchid Pharma corporate actions including splits, bonuses, and buybacks.
Check Orchid Pharma stock events that may affect ORCHPHARMA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 1.08% | ||
| 2026-05-25 | 2026-05-25 | Quarterly Result Announcement | NA | -0.72% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 0.02% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 6.90% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -2.59% |
| 2025-06-26 | 2025-06-26 | Extraordinary General Meeting | NA | 4.93% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | -0.34% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -14.67% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | 7.51% |
| 2024-08-21 | 2024-08-21 | Annual General Meeting | NA | 21.84% |
Orchid Pharma Competitors Screener - Peer Comparison
Screen ORCHPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,581 | 41.43 | 54,729 | 9.71% | 10,980 | 54.75 |
| Divis Laboratories | 182,828 | 73.47 | 9,712 | 18.67% | 2,191 | 66.48 |
| Torrent Pharmaceuticals | 151,833 | 66.60 | 11,539 | 6.99% | 1,911 | 61.90 |
| Cipla | 113,025 | 29.32 | 27,712 | -2.46% | 3,783 | 61.92 |
| Dr Reddys Laboratories | 109,105 | 26.47 | 33,593 | -0.44% | 3,998 | 52.61 |
| Zydus Life Science | 104,543 | 20.35 | 26,720 | 13.65% | 5,242 | 69.40 |
| Lupin | 104,288 | 19.51 | 27,488 | 19.98% | 5,345 | 47.33 |
| Mankind Pharma | 102,351 | 53.58 | 14,278 | 12.03% | 1,750 | 62.34 |
| Aurobindo Pharma | 85,000 | 25.77 | 32,346 | 9.43% | 3,484 | 52.91 |
| Laurus Labs | 72,530 | 81.91 | 6,813 | 21.03% | 884 | 77.10 |
Orchid Pharma Company Announcements - News Screener
Screen ORCHPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-24 | Board Meeting Intimation for Approval Of Audited Financial Results (Standalone & Consolidated) Of The Company For The Quarter-IV And Financial Year Ended On March 31 2026 | - |
| 2026-05-19 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-04-11 | Intimation Under Regulation 30 | - |
| 2026-04-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-07 | Investor Roadshow Scheduled To Be Held On April 10 2026. | - |
| 2026-04-02 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-03-18 | Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (Listing Obligati | - |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-11 | Board Meeting Outcome for Unaudited Limited Review Standalone & Consolidated Financial Results For The Quarter And Year To Date Ended On December 31 2025 | - |
| 2026-02-11 | Quarterly Results | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-06 | Board Meeting Intimation for The Quarter-III Of Financial Year 2025-26 Ended On December 2025. | - |
| 2026-01-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-29 | Closure of Trading Window | - |